With regard to Health Canada’s (HC) Priority Review of Drug Submissions policy (hereinafter the policy): (a) since December 1996, how many submissions have been made under the policy, broken down by year; (b) since December 1996, how many submissions have been approved under the policy, broken down by year; (c) since March 2006, how many submissions have been made under the policy, broken down by year; (d) since March 2006, how many submissions have been approved under the policy, broken down by year; (e) for submissions granted Priority Review status since March 2006, for what percentage of those submissions has HC met its current reduced target time frame for submission screening, broken down by year; (f) for submissions granted Priority Review status since March 2006, for what percentage of those submissions has HC met its current reduced target time frame for submission review, broken down by year; (g) has consideration been given to reducing the current reduced target time frames for submission screening or submission review and, if so, when and in what way; (h) what has been the cost of administering the policy, broken down by fiscal year, since March 2006; (i) what costs or fees are assessed to or required of the originators of submissions to the policy, broken down by type of cost or fee, and how have those costs or fees changed since March 2006; (j) what costs or fees are assessed to or required of the originators of submissions to HC’s non-expedited drug approval process, broken down by type of cost or fee, and how have those costs or fees changed since March 2006; (k) what is the average time, from submission to approval, for submissions made under HC’s non-expedited drug approval process, since March 2006, broken down by year of submission; and (l) what is the average time, from submission to approval, for submissions made under the policy, since March 2006, broken down by year of submission?